Cardinal Health announced its selection by Telix Pharmaceuticals Limited as one of its commercial radiopharmaceutical distributors for Gozellix® (kit for the preparation of gallium-68 gozetotide injection). Gozellix® is Telix’s next-generation PSMA-PET imaging agent for prostate cancer in the United States.
To support the commercial launch in the first half of 2025, Cardinal Health has deployed Telix’s ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology. This enables standardized, high-efficiency, and cost-effective production of cyclotron-produced gallium-68 for use with Gozellix®, facilitating multi-Curie local production.
This partnership builds upon Cardinal Health's existing relationship with Telix, which includes the distribution of Illuccix® and Zircaix®. The collaboration leverages Cardinal Health's extensive commercial distribution structure and innovative production technology to broaden patient reach and scheduling flexibility for gallium-based PSMA imaging.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.